AI assistant
Inventiva — Share Issue/Capital Change 2017
May 8, 2017
1448_dva_2017-05-08_04d2942f-6fa8-479f-8b58-964de4ef313b.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Statement of total voting rights and shares forming the company's share capital tatement capital On May 4, 2017
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Market: Euronext Paris ISIN code / Mnemo: FR0013233012/ IVA Web site: www.inventivapharma.com
| Date | Number of shares outstanding |
Total voting rights, (1) gross |
Total voting rights, net (2) |
|---|---|---|---|
| 4 May 2017 | 16 16,444,477 |
26,474,477 | 26,457,403 |
(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. crossings. In accordance with
(2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 20 11 suspended, i.e. treasury shares (including shares purchased under the liquidity contract) o , contract). It is 2007.
About Inventiva: www.inventivapharma.com
Inventiva is a biopharmaceutical company specialized in the development o receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs. of drugs interacting with nuclear
IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator in controlling the fibrotic process. Its anti medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a approved treatment to date. fibrotic proliferator-activated receptors), which play key roles . anti-fibrotic action targets two initial indications with substantial unmet very high mortality rate and for which there is no f activated fibrotic for three
Inventiva is also developing in parallel, a second clinical product, IVA336, which is a treatment f different forms of mucopolysaccharidosis MPS VI also known as Maroteaux-Lamy syndrome mucopolysaccharidosis: MPS I or Hurler-Scheie syndrome, MPS II or Hunter syndrome and Lamy syndrome. Inventiva has a preclinical stage oncology portfolio.
Inventiva benefits from partnerships with world strategic commercial partnerships, one of which is at clinical stage, Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from the partnerships. world-leading research entities such as the Institut Curie. Two , stage, have also been developed with AbbVie and ndrome, leading art platforms.
Inventiva employs over 100 highly qualified employees and o acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platform owns state-of-the-art R&D facilities near Dijon,
Contacts
Inventiva Frédéric Cren Chief Executive Officer [email protected] +33 (0)3 80 44 75 00
NewCap Julien Perez / Mathilde Bohin Investor Relations [email protected] +33 (0)1 44 71 98 52
NewCap Nicolas Merigeau / Arthur Rouillé Media Relations [email protected] +33 (0)1 44 71 94 98
LifeSci Advisors Chris Maggos Investor Relations [email protected] +41 79 367 6254